We examined human tears for molecules that killed gram-positive bacteria. The principal mediator of bactericidal activity against staphylococci proved to be a calcium-dependent enzyme, secretory phospholipase A 2 . Whereas the concentration of secretory phospholipase A 2 in the normal tear film exceeded 30 g/ml, only 1.1 ng (<0.1 nM) of the enzyme per ml sufficed to kill Listeria monocytogenes and 15 to 80 ng/ml killed Staphylococcus aureus. Despite its efficacy against gram-positive bacteria, secretory phospholipase A 2 lacked bactericidal activity against gram-negative organisms (Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa) when tested in the ionic environment of tears. Given the presence of secretory phospholipase A 2 in tears, intestinal secretions, and leukocytes, this enzyme may play a substantial role in innate mucosal and systemic bactericidal defenses against gram-positive bacteria.
Because the normal cornea lacks blood vessels, many of its host defense needs are supplied by the tear film. Alexander Fleming reported the presence of lysozyme in human tears over 75 years ago and described its ability to lyse and kill Micrococcus leisodeikticus (7, 8) . Later investigators reported that human tears contained a nonlysozyme antistaphylococcal factor that also killed M. leisodeikticus (10, 43) Ford, et al. have advanced (9) and others have challenged (17, 38 ) the possibility that the additional bactericidal factor is "beta-lysin"-an illdefined, heat-stable antimicrobial molecule reportedly present in platelets and plasma (4) . In the absence of more precise knowledge, contemporary ophthalmology texts (23) attribute the antimicrobial properties of tears to their high concentrations of lysozyme, lactoferrin, and immunoglobulin A (IgA) (20) . The experiments described below demonstrate that this conventional belief requires modification and that secretory phospholipase A 2 (sPLA 2 ) is an important host defense molecule in the external eye.
MATERIALS AND METHODS
Tear collection. Tears were collected from six healthy donors, under a protocol approved by the UCLA Institutional Review Board. After approximately 5 l of basal, unstimulated tears had been collected over 2 min into a calibrated 5-l pipette (Accupette; Baxter, McGaw Park, Ill.), the donors were briefly exposed to the vapors of freshly minced onions, and between 100 to 250 l of stimulated tears was collected over the next 5 to 10 min. These tear specimens were stored at Ϫ20°C until tested.
Bacteria. Six strains of Staphylococcus aureus were used. S. aureus GM-1 and 67395 were ocular isolates obtained from the UCLA Clinical Laboratory. The GM-1 strain was gentamicin resistant. Micrococcus luteus ATCC 4698 (previously called Micrococcus leisodeikticus) and a methicillin-resistant S. aureus (MRSA) strain, ATCC 33591, were purchased from the American Type Culture Collection (Rockville, Md.). Six strains (three MRSA, one S. epidermidis, one group B streptococcus, and one vancomycin-resistant Enterococcus faecium strain [VREF 94 .132]) were clinical isolates obtained from the UCLA Clinical Microbiology Laboratory. Bacillus subtilis was a laboratory reference strain, and Listeria monocytogenes EGD was a gift from Pieter Hiemstra.
Artificial tear solution.
Many of our studies were performed with an artificial tear solution (ATS), a balanced salt solution whose composition simulated that of normal human tears (1) . The composition of ATS was 124 mM Na ϩ , 133 mM Cl Ϫ , 24 mM HCO 3 Ϫ , 30 mM K ϩ , 0.7 mM Mg 2ϩ , 0.7 mM Ca 2ϩ , 0.35 mM glucose, 4.5 mM urea, 3.5 mM lactate, and 0.2 mM pyruvate.
Colony counting assays. Mid-logarithmic-phase bacteria were washed with ATS containing 3 mg of Trypticase soy broth powder ml Ϫ1 and adjusted to contain approximately 10 7 CFU ml
Ϫ1
. Samples of pooled tears, purified tear sPLA 2 , lysozyme, or lactoferrin were serially diluted in ATS that had been supplemented with 0.1% bovine serum albumin (ATS-BSA). Bacteria (10 l) were mixed with 90 l of the pooled tear or purified protein samples, so that the final volume (100 l) of ATS contained 0.3 mg of Trypticase soy broth powder ml
. After 15 min, 1 h, or 3 h, aliquots were transferred to Trypticase soy agar plates with a Spiral Plater (SpiralTech, Rockville, Md.), and surviving colonies were counted after overnight incubation at 37°C.
Radial diffusion assays. An extensive description of the assay recently appeared elsewhere (40) . The principal modification introduced for this study involved incorporating ATS and 0.1 mg of albumin ml Ϫ1 (Sigma A-7030) into the underlay gels. The ATS simulated a lachrymal environment, whereas the albumin minimized nonspecific adsorption of sPLA 2 to agarose, especially when ultralow (nanogram) quantities were tested. The underlay contained 4 ϫ 10 6 bacterial CFU dispersed in 10 ml of a gel that contained full-strength ATS, 1% agarose, 0.3 mg of Trypticase soy broth powder ml Ϫ1 , and 0.01% BSA. To prepare bacteria in the logarithmic growth phase, overnight cultures in Trypticase soy broth were subcultured in fresh broth for 2.5 h. These organisms were washed twice with ATS and adjusted to the desired concentrations, based on optical density at 620 nm measurements. Serial "half-log" (i.e., 3.16-fold) dilutions of purified PLA 2 were prepared in ATS-BSA.
A regularly spaced array of 3.2-mm-diameter sample wells, each with a capacity of 9.9 l, was punched into the underlay gels, and 5-l aliquots of the various samples were introduced. After 3 h at 37°C, a 10-ml overlay gel consisting of double-strength (60 g/liter) Trypticase soy broth powder (BBL Microbiology Systems, Cockeysville, Md.) and 1% agarose was poured to enable the surviving bacteria to form visible microcolonies. After overnight incubation at 37°C, the diameters of the clear zones were measured to the nearest 0.1 mm and, after subtraction of the diameter of the well, the difference was expressed in units (1 mm ϭ 10 U). We estimated the minimal bactericidal concentrations by performing linear regression analyses (units vs log 10 concentration) and determining the x-intercepts. The absence of microcolonies in the clear zones surrounding the wells was confirmed by direct microscopy at a ϫ40 magnification.
PLA 2 and lysozyme purification. Tears collected from different donors were pooled and subjected to reverse-phase high-performance liquid chromatography on a Vydac C 18 column (10 by 250 mm) (The Separations Group, Hesperia, Calif.) with a linear gradient of 0 to 60% acetonitrile that contained 0.1% trifluoroacetic acid. Each fraction was examined by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and by the sPLA 2 enzyme assay described below. Fractions with phospholipase activity were combined and rechromatographed on a Vydac C 18 column (4.6 by 250 mm) with a linear gradient of acetonitrile that contained 0.13% heptafluorobutyric acid (HFBA) as the ion-pairing agent. To prepare highly purified human tear lysozyme, we subjected pooled tears to preparative acid urea-PAGE (13) and performed the two-stage RP-HPLC procedure described above for PLA 2 .
Enzymatic assay of PLA 2 . PLA 2 activity was measured essentially as described by Elsbach and Weiss (5 bacteria (adjusted by addition of nonradioactive autoclaved E. coli) in a 250-l volume that contained 250 mM Tris, 10 mM CaCl 2 , and 1 mg of BSA per ml (pH 9.5). After a 1-h incubation in a 37°C shaking water bath, 100 l of 2 N HCl was added to stop the reaction, and the product (free fatty acids and lysophospholipids) was trapped by adding 100 l of 20 mg of fatty acid-free BSA ml
. The mixture was kept at 4°C for 30 min and centrifuged at 10,000 ϫ g for 5 min. The pellet was washed twice with 0.1% acetic acid. The supernatant and washings were combined, and their PLA 2 activity was measured by liquid scintillation counting and converted to arbitrary units (AU [1 AU ϭ 1% release of 14 C]). Immunological assay of PLA 2 . Serially diluted tears and purified tear PLA 2 standards were prepared in 5 l of ATS containing 0.1% BSA. The standards contained 15, 12.5, 10, 7.5, and 5 ng of sPLA 2 per 5 l. One hundred fifty microliters of Tris-buffered saline (20 mM Tris [pH 7.5], 500 mM NaCl) was added to each well of a Bio-Dot SF microfiltration apparatus (Bio-Rad, Hercules, Calif.). Five microliters of the purified tear PLA 2 standards or of a dilution series of tears was added, followed by another 100 l of Tris-buffered saline. The samples were blotted onto a Hybond-ECL (enhanced chemiluminescence) nitrocellulose membrane (Amersham, Arlington Heights, Ill.) at unit gravity. ECL assay reagents were purchased from Amersham, and ECL Western blotting was performed by strictly following the manufacturer's protocols. A murine monoclonal IgG1 antibody to human sPLA 2 was purchased from Upstate Biotechnology (Lake Placid, N.Y.) and used as the primary antibody at 0.5 g/ml. A 1:2,000 dilution of sheep anti-mouse IgG that had been conjugated to horseradish peroxidase (Amersham) was used as the secondary antibody. Light emitted from the luminol substrate after its oxidation by horseradish peroxidase was detected with autoradiography film that was sensitive to blue light (Hyperfilm ECL; Amersham). Densitometry was performed on a Personal Densitometer SI instrument (Molecular Dynamics, Sunnyvale, Calif.) with the manufacturer's ImageQuant software.
Lysozyme. Lysozyme activity was measured by a radial diffusion (lysoplate) assay (30) . The assay plates contained 1% agarose and 0.5 mg of lyophilized M. lysodeikticus per ml in 15 ml of 66 mM sodium phosphate buffer (pH 7.0). Serially diluted samples were dissolved in 5 l of 0.01% acetic acid, placed into 3.2-mmdiameter wells, and incubated overnight at room temperature. Clear zones were measured, and activity was expressed relative to that of highly purified human tear lysozyme standards.
Protein microsequencing. N-terminal sequencing was performed with a Porton model 2090E sequencer (Beckman Instruments, Fullerton, Calif.) after the protein had been reduced, carboxymethylated, and transferred to a polyvinylidene difluoride membrane. Quantitative amino acid analysis was performed by the PicoTag method. The molecular mass of the purified secretory PLA 2 was determined by electrospray ionization-mass spectrometry with a Perkin-Elmer Sciex (Thornhill, Canada) triple-quadrupole electrospray mass spectrometer. The instrument was tuned to resolve the isotopes of the polypropylene glycol-NH 4 ϩ (singly charged ion at m/z 906 with 40% valley) and calibrated by flow injection of a mixture of polypropylene glycol 425, 1000, and 2000 in water-methanol (1/1 [vol/vol]) containing 2 mM ammonium formate and 0.1% acetonitrile. Samples were dissolved in water-acetonitrile-formic acid (50/50/0.1) and injected into a 10-l/min stream of this solvent. Spectra were averaged, and the multiply charged ion series were deconvoluted with the MacSpec and MacBiospec software supplied with the instrument.
Other assays. Protein was measured by the micro-bicinchoninic acid assay, with BSA standards (Pierce, Rockford, Ill.). Table 1 , basal tears contained 13.4 Ϯ 1.28 mg of protein ml Ϫ1 (mean Ϯ standard error) and contained from 8.3 to 17.1 mg of protein ml Ϫ1 . Onion vapor-stimulated tears contained 8.97 Ϯ 0.93 mg of protein ml Ϫ1 and ranged from 5.0 to 11.3 mg of protein ml Ϫ1 . SDS-PAGE analysis confirmed that lysozyme, lactoferrin, and lipocalin were especially abundant ( Fig. 1) .
RESULTS

General composition of tears. As shown in
Antibacterial activity of tears. We performed colony count experiments to test the antimicrobial activity of whole tears against various gram-positive bacteria, including six strains of S. aureus (two clinical ocular isolates and four MRSA strains), L. monocytogenes, B. subtilis, group B Streptococcus, and a vancomycin-resistant E. faecium strain, 94.132. In these studies, 90 l of pooled tears and 10 l (10 5 CFU) of bacteria were mixed together and incubated for 3 h at 37°C in a shaking water bath. As shown in Table 2 , over 99% of the bacteria had 2 , and lysozyme in basal and onion vapor-stimulated tears were compared by paired t tests. P Ͻ 0.05 for protein basal versus stimulated, and P Ͻ 0.01 for all other basal versus stimulated comparisons within the same column. Lane A (5 l of pooled tears) displays three major bands, which have been numbered. They correspond to the following proteins: 1, lysozyme; 2, tearspecific prealbumin (also called lipocalin); and 3, lactoferrin. Lane B shows the PLA 2 -containing fractions after the first stage of RP-HPLC purification. Lane C shows highly purified PLA 2 after the second stage of RP-HPLC purification, with an acetonitrile (ACN) gradient in 0.13% HFBA. The panel on the right shows the sPLA 2 peak, monitored at 230 nm, and is from the second HPLC purification step.
been eradicated after 1 h, and essentially complete (99.99%) eradication of the organisms was accomplished by 3 h.
Fractionation of tears. To ascertain which components of human tears were responsible for their activity against grampositive bacteria, we fractionated normal tears by RP-HPLC. Fractions were collected each minute, lyophilized by vacuum centrifugation, redissolved in acidified water (0.01% acetic acid), and tested against L. monocytogenes EGD in radial diffusion assays. The underlay gels contained 10 mM sodium phosphate buffer, 1% agarose, and 0.3 mg of Trypticase soy broth powder per ml Ϯ 100 mM NaCl, without supplemental calcium. As shown in Fig. 2 , two distinct antibacterial peaks were present, one centered around fraction 42 and the other centered around fraction 52. The antimicrobial molecules in fraction 42 were almost equally active under low-and high-salt conditions (10 mM phosphate buffer Ϯ 100 mM NaCl). In contrast, those in fraction 52 were considerably more active under the low-salt conditions (10 mM phosphate buffer). Enzymatic assays revealed that fraction 42 contained the highest PLA 2 activity and that fraction 52 corresponded to the lysozyme peak.
Purification of PLA 2 . Tears were collected from the six donors, pooled, and subjected to RP-HPLC. When the partially purified fractions with PLA 2 activity were examined by SDS-PAGE, they contained two principal components, both with apparent masses of approximately 14 kDa (Fig. 1, lane B) . These proteins were resolved and purified by rechromatography of the fractions on the same C 18 column with 0.13% HFBA as the ion-pairing reagent. The partial N-terminal sequence (residues 1 to 22) of the more abundant protein was identical to that of human type II sPLA 2 : NLVNF HRMIK LTTGK EAALS YG. The molecular mass of the purified molecule was 13,905.2 Da by electrospray ionization-mass spectrometry which was in close agreement with the expected mass of 13,903.7, calculated from the molecule's primary sequence (36) . In addition, the purified molecule reacted with a monoclonal antibody to human sPLA 2 in Western blots (data not shown). This constellation of findings (N-terminal sequence, mass, and immunological reactivity) securely established the molecule's identity as sPLA 2 . The N-terminal sequence of the other peptide present in Fig. 1, lane B , corresponded precisely to that of serum leukoprotease inhibitor (SLPI), and this molecule also reacted strongly to a polyclonal antibody against human recombinant SLPI (data not shown). Figure 1 , lane C, shows highly purified sPLA 2 , after its resolution from SLPI by the second RP-HPLC. The right panel of Fig. 1 shows the RP-HPLC chromatogram of purified human tear sPLA 2 .
Quantitation of tear sPLA 2 . The sPLA 2 concentration in tears of six healthy individuals was measured by two methods: one enzymatic and the other immunochemical. The enzymatic assay used [
14 C]oleate-labeled autoclaved E. coli as a substrate. The immunoassay was an ECL procedure using a murine monoclonal antibody to human sPLA 2 . Highly purified human tear PLA 2 was used as the standard in both assays. In Western blotting experiments with whole tears, the monoclonal antibody stained only sPLA2 and detected Ͻ1 ng of sPLA 2 when we used an alkaline phosphatase-conjugated secondary antibody (data not shown). The ECL assay was even more sensitive, and its output on film was better suited to densitometry. Figure 3 shows a representative standard curve from the ECL assay of sPLA 2 .
As shown in Table 1 , basal tears contained 36.7 Ϯ 2.99 g of PLA 2 ml Ϫ1 determined by ECL immunoassay and 32.1 Ϯ 5.4 g of sPLA 2 ml Ϫ1 determined by the enzymatic assay. Stimulated tears contained 27.4 Ϯ 2.19 g of PLA 2 ml Ϫ1 by the ECL immunoassay system but only 14.9 Ϯ 2.62 g of sPLA 2 ml Ϫ1 by enzymatic assay. In two separate purifications, we recovered a total of 218 g of highly purified PLA 2 from 21 ml of pooled stimulated tears (10.4 g ml Ϫ1 ), as determined by quantitative Antimicrobial activity of tear PLA 2 . Purified PLA 2 was highly effective against all of the gram-positive bacteria we tested (Fig. 4 and 5) . The minimal effective concentration of sPLA 2 against the various organisms, indicated by their respective x-intercepts, varied over a large range in the experiments shown in Fig. 4 Figure 5 compares the effects of sPLA 2 , lysozyme, and lactoferrin on two additional gram-positive bacteria, S. epidermidis and M. luteus. The latter is the same strain (originally called M. leisodeikticus) that Fleming used in his pioneering studies with lysozyme. The M. luteus strain was killed by Ϸ13 g of lysozyme ml
Ϫ1 and by Ϸ0.3 g of sPLA 2 ml Ϫ1 . Both of these concentrations are approximately 100-fold lower than the concentrations of these enzymes in normal tears (Table 1) . sPLA2, but not lysozyme, showed bactericidal activity against S. epidermidis. Lactoferrin was inactive against both of these organisms.
In contrast to its efficacy against gram-positive bacteria, even 25 g of sPLA 2 ml Ϫ1 failed to kill gram-negative bacteria, including E. coli, S. typhimurium, and P. aeruginosa in radial diffusion assays performed with underlay gels that contained ATS. However, when these assays were performed with lowsalt underlays (10 mM sodium phosphate buffer), sPLA2 showed bactericidal activity against these gram-negative bacteria (data not shown), consistent with our previous report on intestinal sPLA 2 (14) .
Rapidity of the effect. Figure 6 shows that sPLA 2 acted rapidly after addition to 1.5 ϫ 10 6 to 3 ϫ 10 6 bacteria ml Ϫ1 in artificial tear fluid. After 15 min of incubation, as little as 100 ng of sPLA 2 ml Ϫ1 totally eradicated L. monocytogenes EGD and 5 g ml Ϫ1 eradicated S. aureus 67395.
Effects of divalent cations.
To determine the degree to which the bactericidal activity of sPLA 2 was calcium dependent, we performed the experiments shown in Fig. 7 . The basic unsupplemented underlay gels contained 1% agarose, fullstrength calcium-and magnesium-free ATS, and 0.3 mg of Trypticase soy broth powder per ml. The addition of 0.7 mM CaCl 2 to these underlay gels enhanced the bactericidal potency of PLA 2 over 1,000-fold, whereas addition of 2 mM EGTA, a selective Ca 2ϩ chelator, abolished its antimicrobial activity even when the gels also contained 0.7 mM calcium. The slight activity of sPLA 2 in underlay gels without specifically added calcium (Fig. 7, solid circles) probably reflects the effects of the calcium contained in Trypticase soy broth powder, since it was also abolished by addition of EGTA. In retrospect, we were lucky to have selected L. monocytogenes, which is exquisitely sensitive to sPLA 2 , for the preliminary studies shown in Fig. 2 , since the very low concentrations of calcium that were present in the underlay were markedly suboptimal for sPLA 2 .
Antimicrobial activity of other tear components. The calcium dependence of sPLA 2 -mediated antimicrobial activity Radial diffusion assays were performed with purified human tear sPLA 2 , human tear lysozyme, and human milk lactoferrin. Note that the MIC (x-intercept) of sPLA 2 for M. luteus (F) was approximately 0.3 g/ml, whereas that of lysozyme was 13 g/ml. The MIC of sPLA 2 for S. epidermidis (ᮀ) was approximately 0.15 g/ml, whereas lysozyme was not effective (MIC of Ͼ1.5 mg/ml). against gram-positive bacteria and especially its abolition by EGTA provided a facile method for determining if additional antimicrobial molecules contributed to the antimicrobial properties of tears against gram-positive bacteria. As shown in Table 3 , the addition of 2 mM EGTA to normal tears completely blocked its activity against all six S. aureus strains, including the four MRSA strains. In contrast, the activity of tears against L. monocytogenes and group B Streptococcus was only partially blocked, and EGTA-containing tears retained their activity against E. faecium and B. subtilis.
Since both lactoferrin and lysozyme are both abundant in human tears and have antimicrobial potential, we tested them against the four bacterial species killed in EGTA-supplemented tears (Table 4) . Although a high (1.5 mg/ml), but physiological concentration of highly purified human tear lysozyme eradicated more than 99.99% of E. faecium and B. subtilis in 1 h, it showed no activity against group B Streptococcus and only bacteriostatic activity against L. monocytogenes (data not shown). Human milk lactoferrin (1.5 mg/ml) displayed modest bactericidal activity only against B. subtilis, and it was inactive against the other three bacteria. Thus, whereas lysozyme might account for the activity of EGTA-treated tears against E. faecium and B. subtilis, the residual activity of EGTA-treated tears against L. monocytogenes and group B Streptococcus may reflect the actions of other, as yet unidentified, tear components.
DISCUSSION
Human sPLA 2 is a 13.9-kDa molecule composed of 124 amino acid residues. It has been found in many tissues and secretions, including rheumatoid synovial fluids (37), platelets (21), seminal plasma (29, 41) , intestinal Paneth cells (27) , and neutrophils (32) . The levels of sPLA 2 in seminal plasma were reported to range between 15 and around 30 g/ml (29)-very similar to the levels we found in the tear film (Table 1) . It is noteworthy that sPLA 2 hydrolyzes phosphatidylglycerol several hundred times more rapidly than phosphatidylcholine, since the former is a principal phospholipid of microbial membranes, whereas the latter is typically abundant in mammalian cell membranes (24, 25, 44) .
All PLA 2 enzymes (EC 3.1.1.4) hydrolyze the sn-2 fatty acyl moiety from phospholipids, releasing equimolar amounts of free fatty acids and lysophospholipids. Over 60 secretory PLA 2 enzymes were reviewed by Scott and Sigler (34, 35) , who described sPLA 2 enzymes as robust, small molecules that were highly resistant to denaturation and preferred substrates that were organized into micelles, monolayers, or membranes. All sPLA 2 enzymes bind calcium ions with a K d of Ͼ10 Ϫ4 M, and this cation is essential for catalysis. The various PLA 2 enzymes show strongly conserved three-dimensional structures that are stabilized by multiple intramolecular cystine disulfide bonds. Although mammalian sPLA 2 s are often described according to their tissues of origin, (e.g., pancreatic, splenic, or intestinal PLA 2 ), only a single sPLA 2 gene exists in humans (37) . Type I and type II PLA 2 enzymes are distinguished by the location of one of their seven disulfide bridges and by a seven-residue C-terminal extension found only in the type II PLA 2 s. Type I PLA 2 is exemplified by mammalian pancreatic enzymes and homologs found in Old World elapid snake venoms, whereas the type II enzymes include intestinal and splenic PLA 2 s and venom constituents of New World viperid and crotalid snakes (16, 18) . Additional PLA 2 enzymes that are structurally and functionally distinct from the type I and II enzymes are also found in mammalian cells and may be especially important in mediating cellular injury (3, 33) .
Our experiments demonstrated that remarkably large con- (26) . Using a time-resolved fluoroimmunoassay procedure, these investigators reported that tears contained 1.45 g of sPLA2 ml Ϫ1 , a value 10-to 20-fold lower than the sPLA 2 concentrations shown in Table 1 . Since we used both an enzymatic assay and an immunoassay procedure to determine these sPLA 2 concentrations, we are confident that the concentrations shown in Table 1 are accurate. This belief is reinforced by our ability to recover 10.4 g of highly purified sPLA 2 ml Ϫ1 from tears by the two-stage HPLC procedure described above. The earlier study of sPLA 2 in tears was performed in a country (Finland) whose population is unusually homogeneous (15) . Consequently, it is noteworthy that the two ethnic Finns in our donor group had sPLA 2 concentrations in their tears similar to those found in the Asian or Caucasian donors (Table 1) .
Whereas we obtained nearly identical values (36.7 versus 32.1 g/ml) for the concentration of sPLA 2 in basal tears with the enzymatic and immunological assays, the assays gave divergent results (27.4 versus 14.9 g/ml) when applied to onion vapor-stimulated tears. Our preliminary evidence suggests that the lower sPLA 2 activity in stimulated tears reflects the presence of an sPLA 2 inhibitor, as yet unidentified (data not shown). Endogenous sPLA 2 inhibitors also exist in bovine seminal plasma (22) .
Our data provide compelling evidence that sPLA 2 is principally responsible for the ability of tears to kill a broad spectrum of gram-positive bacteria, notwithstanding the presence of lysozyme and lactoferrin in much higher concentrations. This inference is supported by several lines of evidence. First, concentrations of purified human sPLA 2 much lower than those present in tears showed potent bactericidal activity against each of the gram-positive bacteria in our panel. This bactericidal activity was calcium dependent and was also inhibited by EGTA, suggesting that the enzymatic effects of sPLA 2 were critical for its bactericidal properties. Second, 2 mM EGTA abolished the bactericidal effect of normal tears against normal and MRSA strains and greatly reduced their activity against group B streptococci and L. monocytogenes (Tables 2 and 3 ). Lysozyme and lactoferrin displayed little or no activity against these organisms, even when tested at 1.5 mg/ml. As might be expected, EGTA did not inhibit the activity of tears against highly lysozyme-susceptible bacteria, such as B. subtilis, and a vancomycin-resistant strain of E. faecium.
Not withstanding its high concentration, our data indicate that lysozyme acts in a secondary (backup) manner with respect to the bactericidal properties of human tears against gram-positive bacteria. The reported absence of lysozyme from the tears of cattle is consistent with its secondary role in this respect (31) . Inbred mouse strains, including the widely used C57BL/6 strain, that are naturally deficient in sPLA2 because of a frameshift mutation in exon 3 of the gene (19) may afford useful models for defining the role of sPLA 2 in mucosal and secretory host defenses.
Both murine intestinal (14) and rabbit leukocyte (45) sPLA 2 possess bactericidal properties. The potent activity of rabbit leukocyte sPLA 2 against S. aureus largely accounted for the staphylocidal activity of a sterile inflammatory peritoneal exudate fluid which contained 10 nM (0.14 g/ml) of sPLA 2 (45) . Whereas normal human serum contains low levels of sPLA 2 that circulate mostly in high-molecular-weight complexes (28) , the concentration of sPLA 2 in human serum rises sharply during sepsis (6, 12) . sPLA 2 causes bacterial phospholipid degradation during phagocytosis of E. coli cells by polymorphonuclear leukocytes and also degrades the phospholipids of E. coli cells treated with neutrophil-derived bactericidal, permeability-increasing protein (46) .
The remarkable susceptibility of L. monocytogenes to human secretory PLA 2 (Fig. 4) has an ironic aspect, since this organism uses two secreted phospholipases-a phosphatidylinositolspecific phospholipase C and a broad-range phospholipase C-to escape from vacuoles of the host's phagocytes and spread from cell to cell (2, 39) .
The development of molecules that can inhibit PLA 2 activity is a major area of pharmaceutical research (11, 42) , in part stimulated by the belief that the elevated concentrations of sPLA2 in the inflammatory fluids, plasma, and infected tissues are noxious. The present report and other recent demonstrations (14, 45) that sPLA 2 has potent microbicidal properties suggest that its induction and release may be beneficial to hosts with infections caused by gram-positive bacteria. Should sPLA 2 inhibitors enter into routine clinical use, it will be important to be watchful for evidence of impaired host resistance or of increased infections caused by gram-positive organisms.
